Search
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnAs a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting
N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14196ApprovedN-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. … Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.
NCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
CA-074 methyl ester
go.drugbank.com/drugs/DB07223ExperimentalCA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. It is converted by cellular esterases to CA-074.[A258234,A258239]
Synonyms: Methyl N-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-isoleucyl-L-prolinate, L-Proline, N-[[(2S,3S)-3-[(propylamino)carbonyl]oxiranyl]carbonyl]-L-isoleucyl-, methyl esterRezivertinib
go.drugbank.com/drugs/DB21471InvestigationalRezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Rezivertinib is a epidermal growth factor receptor (EGFR) inhibitor.
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigationalSomapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).
Garlic oil
go.drugbank.com/drugs/DB15989InvestigationalCategories: Compounds used in a research, industrial, or household settingSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Axitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalAxitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index